Treatment of Tourette's Syndrome with RO22–1319, a D-2-Receptor Antagonist

Publisher Website
Google Scholar
Abstract
To the Editor: Haloperidol is the current treatment of choice for Tourette's syndrome.1 However, the reduction of motor and vocal tics in response to this nonspecific dopamine-receptor blocker is often limited by adverse effects, which can prevent treatment with a dosage adequate for symptom control or lead to noncompliance. The extrapyramidal side effects of haloperidol are assumed to result from nigrostriatal dopamine-receptor blockade.1 RO22–1319, representing a new class of drugs designed for three-dimensional computer models of receptors, is a novel dopamine-receptor antagonist.2 It is a water-soluble pyrroloisoquinoline derivative, whose chemical structure is different from that of other antipsychotic agents (rac. . . .